Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Catheter Precision ( (VTAK) ).
On April 21, 2026, Catheter Precision closed the sale of 3,470 shares of its newly created Series C-2 Convertible Preferred Stock at $1,000 per share, raising gross proceeds of $3.47 million to be used for working capital and general corporate needs. The Series C-2 shares, approved by stockholders on April 15, 2026, are convertible into common stock at an initial price of $0.883 per share, subject to a $0.35 floor, anti-dilution protections and beneficial ownership caps, and were placed through Dawson James Securities in a private offering to accredited investors.
On April 20, 2026, in connection with its previously disclosed acquisition of Fly Flyte, Inc., the company issued 11,028 shares of newly designated Series D Convertible Preferred Stock, valued at $1,000 per share, to SEG Jets LLC and Creatd, Inc. as equity consideration for their stakes in Flyte. The Series D shares are convertible into common stock at an initial price of $1.1038 per share, with a post-registration adjustment mechanism, a $0.35 floor, and similar ownership and anti-dilution limits, underscoring Catheter Precision’s reliance on structured equity to finance acquisitions while managing potential dilution for existing shareholders.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.
The score is held down primarily by persistent large losses and significant cash burn relative to revenue, alongside a pronounced downtrend in the stock. The recent financing and liability conversions improve liquidity prospects and provide some offset, but valuation remains unattractive due to ongoing unprofitability and no dividend support.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Catheter Precision, Inc. operates in the medical technology sector, focusing on catheter-based devices and related innovations for cardiovascular and electrophysiology applications. The company accesses capital markets through preferred and common stock issuances to fund working capital and general corporate purposes, and it has recently expanded via acquisitions, including Fly Flyte, Inc.
Average Trading Volume: 1,160,020
Technical Sentiment Signal: Sell
Current Market Cap: $2.56M
Learn more about VTAK stock on TipRanks’ Stock Analysis page.